Overview

RDEA119 and Sorafenib Combination Dose Escalation Study

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Phase 1/2 dose escalation study to investigate the combination of RDEA119 and sorafenib in advanced cancer patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Niacinamide
Sorafenib